Work on a vaccine against Ebola virus suspended
Two companies, which are now also facing prototype vaccine, reported that funding for their work by the Ministry of Defense in recent weeks, suspended, reports Russian service of BBC. p>
Ebola virus is the causative agent of one of the most dangerous infectious diseases – haemorrhagic Ebola. It causes severe bleeding, which leads to death within two weeks. Outbreak of the disease in Uganda earlier this summer, claimed the lives of 16 people. The mortality rate of cases with Ebola reaches 90%.
Undertake development of vaccines funded by the U.S. Department of Defense and the National Institutes of Health, as a result created several prototypes of possible vaccines that have proven effective in animal tests. Then the two companies, Sarepta and Tekmira, began human trials. But recently, the two companies have been ordered by the Ministry of Defense to suspend operations due to reduced funding. Gene Olinger, a virologist at the Institute of Infectious Diseases of the U.S. Army, said that with the current level of funding, the vaccine could be obtained in 5-7 years.
But none of the major pharmaceutical companies have invested in the development of vaccines against Ebola virus. After the discovery of the virus in 1976, they became infected only 2200 people. Fever occurs spontaneously and kills infected very quickly. This limits not only the spread of the disease, but the commercial potential of drugs from her.
Uncertain prospects of public funding and the complete lack of interest from major pharmaceutical companies make some scientists questioned whether the vaccine against Ebola virus when- or will be born.